Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc.

80.50
EUR
-1.00
(-1.23%)
-3.46EPS
4.28BMarket Cap
Mar 16Next Earn

Total Valuation

EUR

As of September 30, 2026, Dianthus Therapeutics, Inc. carries a market capitalization of 4.28B, placing it among publicly traded companies globally. Its enterprise value stands at 3.54B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.28B
Enterprise Value3.54B

Important Dates

Dianthus Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 16, 2027.

Earnings Date3/16/2027

Share Statistics

As of September 30, 2026, Dianthus Therapeutics, Inc. has 56.30M shares outstanding.

Shares Outstanding56.30M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 1,635.10, and the price-to-book ratio stands at 3.91.

PS Ratio1,635.10
PB Ratio3.91
P/TBV Ratio3.91
P/FCF Ratio-25.37
P/OCF Ratio-25.37

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 1,476.31 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.54B versus a market cap of 4.28B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1,476.31

Financial Position

As of September 30, 2026, Dianthus Therapeutics, Inc. maintains a current ratio of 30.02, meaning it holds 30.0x the short-term assets needed to cover near-term liabilities.

Current Ratio30.02
Quick Ratio29.40
Debt / Equity0.10
Debt / EBITDA-0.01

Financial Efficiency

EUR

Over the twelve months ended September 30, 2026, Dianthus Therapeutics, Inc. posted a negative return on equity (ROE) of -22.61, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -21.81, reflecting losses generated across the asset base. The company generates approximately 26,066.21 in revenue per employee across its workforce of 92.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-22.61
Return on Assets (ROA)-21.81
Revenue Per Employee26,066.21
Employee Count92.00

Stock Price Statistics

EUR

As of the close on November 17, 2026, Dianthus Therapeutics, Inc.'s stock has gained approximately 127.40% over the past 52 weeks. The 50-day moving average sits at 77.44, while the 200-day moving average is 75.54.

52-Week Price Change127.40%
50-Day Moving Average77.44
200-Day Moving Average75.54

Income Statement

EUR

Over the twelve months ended September 30, 2026, Dianthus Therapeutics, Inc. generated 2.40M in revenue and converted that into -178.33M in net income, yielding earnings per share of -3.46. EBITDA reached -207.90M, while operating income came in at -208.25M.

Revenue2.40M
Operating Income-208.25M
Pretax Income-178.33M
Net Income-178.33M
EBITDA-207.90M
EBIT-208.25M
Earnings Per Share (EPS)-3.46

Balance Sheet

EUR

As of September 30, 2026, Dianthus Therapeutics, Inc. holds 739.18M in cash and equivalents against 1.07M in total debt, resulting in a net debt position of -49.13M. Total book value stands at 1.10B, with working capital of 730.12M providing operational flexibility.

Cash & Cash Equivalents739.18M
Total Debt1.07M
Net Debt-49.13M
Equity (Book Value)1.10B
Book Value Per Share19.46
Working Capital730.12M

Cash Flow

EUR

Dianthus Therapeutics, Inc. produced -154.54M in operating cash flow over the twelve months ended September 30, 2026.

Operating Cash Flow-154.54M
Free Cash Flow-154.54M
FCF Per Share-3.00

Margins

These figures cover the twelve months ended September 30, 2026. The operating margin of -8,683.89 and net profit margin of -7,436.50 provide insight into operational efficiency.

Operating Margin-8,683.89
Pretax Margin-7,436.50
Profit Margin-7,436.50
EBITDA Margin-8,669.57

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -3.94: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -17.78, meaning Dianthus Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-17.78
FCF Yield-3.94

Stock Splits

Dianthus Therapeutics, Inc.'s most recent stock split took place on September 12, 2023 with a 16:1 split ratio.

Last Split Date9/12/2023
Split Ratio16:1

Scores

As of September 30, 2026, Dianthus Therapeutics, Inc. has an Altman Z-Score of 83.20, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score83.20